PT - JOURNAL ARTICLE AU - Bilal Malik AU - Atefeh Kalantary AU - Kamal Rikabi AU - Arvind Kunadi TI - Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine AID - 10.1136/bcr-2021-243975 DP - 2021 Jul 01 TA - BMJ Case Reports PG - e243975 VI - 14 IP - 7 4099 - http://casereports.bmj.com/content/14/7/e243975.short 4100 - http://casereports.bmj.com/content/14/7/e243975.full SO - BMJ Case Reports2021 Jul 01; 14 AB - As with past illnesses, an approach has been taken to vaccinate the population and halt the spread of COVID-19. On 13 April 2021, the US Food and Drug Administration called for a halt in the administration of the Johnson & Johnson (J&J) COVID-19 vaccine due to reports of thrombosis and thrombocytopenia being associated with vaccination. We present the case of a 43-year-old woman with a history of dyslipidaemia, depression, gastro-oesophageal reflux disease and obesity presenting with dyspnoea, headache and light headedness of 3 days’ duration. Ten days prior, she had received the J&J COVID-19 vaccine. She was found to have thrombocytopenia, elevated D-dimers, pulmonary emboli and presented 1 day after discharge with an arterial clot despite being on apixaban. Six other US-based cases of venous thrombotic events are being reviewed at present. Patients should be informed of the possibility of such events to provide informed consent.